We are live on
!
Find out more
LS
Livforsakringsbolaget Skandia Portfolio holdings
AUM
$2.58B
1-Year Est. Return
30.64%
This Fund
S&P 500
This Quarter
Est. Return
+5.89%
1 Year Est. Return
+30.64%
3 Year Est. Return
+115.62%
5 Year Est. Return
+153.42%
10 Year Est. Return
+554.99%
AUM
$1.89B
AUM Growth
+$29.4M
(+1.6%)
Cap. Flow
-$29.2M
Cap. Flow
% of AUM
-1.54%
Top 10 Holdings %
Top 10 Hldgs %
40.85%
Holding
614
New
19
Increased
46
Reduced
135
Closed
42
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$18.6M |
| 2 |
United Rentals
URI
|
+$16.2M |
| 3 |
Visa
V
|
+$15.4M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$11.9M |
| 5 |
United Therapeutics
UTHR
|
+$10.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$13.6M |
| 2 |
Ferguson
FERG
|
+$11.1M |
| 3 |
Advanced Micro Devices
AMD
|
+$7.7M |
| 4 |
Pfizer
PFE
|
+$7.2M |
| 5 |
Arista Networks
ANET
|
+$5.93M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.53% |
| 2 | Consumer Discretionary | 15.92% |
| 3 | Financials | 13.7% |
| 4 | Healthcare | 11.36% |
| 5 | Communication Services | 11.09% |
Similar funds
GFA
AAS
DCM
PCM
HWA
GAG
ECP
RCMF
Livforsakringsbolaget Skandia's Q4 2024 Portfolio in Review
As of Q4 2024, Livforsakringsbolaget Skandia held 614 positions worth $1.89B, up 1.6% from $1.86B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Livforsakringsbolaget Skandia's Q4 2024 filing shows 19 new, 46 increased, 135 reduced and 42 closed positions. Its largest new stake was Unum: 67,500 shares worth $4.93M. The largest sale was Merck, an estimated $13.6M.
By sector, the portfolio is most concentrated in Technology at 36% of assets, up from 35% a quarter earlier, followed by Consumer Discretionary and Financials.
- Livforsakringsbolaget Skandia's largest Q4 2024 buy was Unum: 67,500 shares worth $4.93M.
- Livforsakringsbolaget Skandia added most to UnitedHealth in Q4 2024, an estimated $18.6M increase.
- Livforsakringsbolaget Skandia's biggest Q4 2024 reduction was Merck, cutting an estimated $13.6M.
- Livforsakringsbolaget Skandia fully exited Catalyst Pharmaceutical in Q4 2024, selling an estimated $2.2M.
- Livforsakringsbolaget Skandia's ten largest holdings make up 41% of its $1.89B portfolio in Q4 2024.
- Livforsakringsbolaget Skandia opened 19 new positions and closed 42 in Q4 2024.
- Livforsakringsbolaget Skandia's portfolio value rose 1.6% quarter-over-quarter to $1.89B.
Based on Livforsakringsbolaget Skandia's 13F filing for Q4 2024, filed 28 Jan 2025.